Novocure (NASDAQ: NVCR) reported Q4 EPS of ($0.36), $0.06 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $128.43 million versus the consensus estimate of $129.27 million.

For earnings history and earnings-related data on Novocure (NVCR) click here.